The Broader Economic Value of Treatment for Diabetic Macular Edema
Authors' conclusion
Treatment for DME provides economic value to patients and society through improved vision, life expectancy, and quality of life and indirectly through improved employment and disability outcomes.
Study context
- Population
- Simulated individuals with diabetic macular edema (DME); representative 51-year-old; U.S. DME cohort (1.1. million people)
- Exposure
- DME treatment vs untreated
- Outcome
- SRV and economic outcomes, treated vs untreated
- Follow-up
- Lifetime horizon
Methodological detailsmicrosimulation and cohort-level analysis, microsimulation model, lifetime horizon, cohort-level analysis based on real-world treatment parameters
- Microsimulation and cohort-level analysis
- Microsimulation model
- Lifetime horizon
- Cohort-level analysis based on real-world treatment parameters
Main finding
As reported in the abstract
lifetime horizon
- Additional years with excellent/good self-reported vision (SRV), treated vs untreated
- 30-35%
- Fewer years with fair/poor SRV, treated vs untreated
- 29-32%
- Greater life expectancy, treated
- 4-5%
- More quality-adjusted life-years, treated
- 9-13%
- More years working, treated
- 6-9%
- Greater lifetime earnings, treated
- 12-19%
- Fewer years with disability, treated
- 8-16%
Observational data: associations, not effects.
Further findings
U.S. DME cohort benefits and net value · 20 years
- Total direct benefit
- $63.0 billion
- Total indirect benefit
- $4.8 billion
- Net value (benefit - cost) of treatment
- $28.1 billion to $52.8 billion
Original publication
The Broader Economic Value of Treatment for Diabetic Macular Edema. Diabetes Care. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →